SCHEMBL4904440

SCHEMBL4904440

Cc1cc(S(=O)(=O)NCCc2ccc(Oc3ccc(OC(F)(F)F)cc3)cc2)cc(C(=O)O)c1C

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.47
EPHX2 P34913 1/20 0.47
AKR1C3 P42330 3/20 0.46
ALDH1A1 P00352 5/20 0.45
SMN1; SMN2 Q16637 1/20 0.43
TBXA2R P21731 1/20 0.43
TBXAS1 P24557 1/20 0.43
POLB P06746 1/20 0.41
MMP2 P08253 2/20 0.41
MMP9 P14780 2/20 0.41
TP53 P04637 1/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
GAA P10253 1/20 0.40
FFAR4 Q5NUL3 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
TRPM8 Q7Z2W7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4897453 0.94 AKR1C3 (0.46) LTA4HEPHX2AKR1C3ALDH1A1SMN1; SMN2
SCHEMBL4904169 0.92 ALDH1A1 (0.46) LTA4HEPHX2AKR1C3ALDH1A1SMN1; SMN2
SCHEMBL4906290 0.91 LTA4H (0.47) LTA4HEPHX2AKR1C3ALDH1A1SMN1; SMN2
SCHEMBL4906257 0.90 ALDH1A1 (0.54) LTA4HEPHX2AKR1C3ALDH1A1SMN1; SMN2
SCHEMBL4903984 0.90 AKR1C3 (0.53) EPHX2AKR1C3ALDH1A1SMN1; SMN2TBXA2R
SCHEMBL4907127 0.89 LMNA (0.51) LTA4HEPHX2AKR1C3ALDH1A1SMN1; SMN2
SCHEMBL4900618 0.88 PKM (0.48) AKR1C3ALDH1A1SMN1; SMN2TBXA2RTBXAS1
SCHEMBL4895621 0.88 AKR1C3 (0.53) AKR1C3ALDH1A1TBXA2RTP53MEN1
SCHEMBL4897493 0.87 TP53 (0.46) AKR1C3ALDH1A1SMN1; SMN2TBXA2RTBXAS1
SCHEMBL4905199 0.87 HTT (0.53) AKR1C3ALDH1A1SMN1; SMN2TBXA2RTBXAS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080090829-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PFIZER INC. 2008-04-17 US disclosed
US-20080090829-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PFIZER INC. 2008-04-17 US disclosed
US-20080090829-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PFIZER INC. 2008-04-17 US disclosed
US-20050288340-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER INC 2005-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288340-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PPARA, PPARG, PPARD LTA4H 2962/4885EPHX2 3463/4885AKR1C3 1645/4885
US-20080090829-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PPARA, PPARG, PPARD LTA4H 2962/4885EPHX2 3463/4885AKR1C3 1645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.